In addition, various reports have confirmed that BRD7 expression is down-regulated and significantly correlates with clinical outcomes in a broad range of malignant tumors, such as osteosarcoma, prostate cancer, colorectal cancer and epithelial ovarian carcinoma [19-22]. Here, BRD7 is linked to osteosarcoma.